BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 210235)

  • 21. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.
    Frossard N; Landry Y; Pauli G; Ruckstuhl M
    Br J Pharmacol; 1981 Aug; 73(4):933-8. PubMed ID: 6168323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
    Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
    Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
    Wachtel H
    Psychopharmacology (Berl); 1982; 77(4):309-16. PubMed ID: 6182575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.
    Weiss RM; Wheeler MA
    J Pharmacol Exp Ther; 1988 Nov; 247(2):630-4. PubMed ID: 2846825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
    Torphy TJ; Zhou HL; Burman M; Huang LB
    Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
    Souness JE; Diocee BK; Martin W; Moodie SA
    Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective alteration of Ca2+-dependent and Ca2+-independent cyclic nucleotide phosphodiesterase activity in rat cerebral cortex by cyclic nucleotides and their analogs.
    Davis CW
    Biochim Biophys Acta; 1982 Jul; 705(1):1-7. PubMed ID: 6288105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissimilar cyclic nucleotide phosphodiesterase activities in subcellular fractions from normal and SV40-transformed WI-38 fibroblasts.
    Nemecek GM; Butcher RW
    J Cyclic Nucleotide Res; 1979 Dec; 5(6):449-61. PubMed ID: 94064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase inhibitors: their comparative effectiveness in vitro in various organs.
    Adachi K; Numano F
    Jpn J Pharmacol; 1977 Feb; 27(1):97-103. PubMed ID: 194077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.
    Brackeen MF; Cowan DJ; Stafford JA; Schoenen FJ; Veal JM; Domanico PL; Rose D; Strickland AB; Verghese M; Feldman PL
    J Med Chem; 1995 Nov; 38(24):4848-54. PubMed ID: 7490734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
    Xin ZC; Kim EK; Lin CS; Liu WJ; Tian L; Yuan YM; Fu J
    Asian J Androl; 2003 Mar; 5(1):15-8. PubMed ID: 12646997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. Relevance to the spasmolytic and anti-spasmogenic actions of AH 21-132 in the intact tissue.
    Giembycz MA; Barnes PJ
    Biochem Pharmacol; 1991 Jul; 42(3):663-77. PubMed ID: 1650218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The identification and characterization of two cyclic nucleotide phosphodiesterases from bovine adrenal medulla.
    Sabatine JM; Coffee CJ
    Arch Biochem Biophys; 1986 Aug; 249(1):95-105. PubMed ID: 3017224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bovine luteal cyclic AMP and cyclic GMP phosphodiesterase activity; sensitivity to various drugs and hormones.
    Goff AK; Major PW
    FEBS Lett; 1976 Jan; 61(2):144-7. PubMed ID: 174943
    [No Abstract]   [Full Text] [Related]  

  • 39. Differential effects of two phosphodiesterase inhibitors on fat cell metabolism.
    Shechter Y
    Endocrinology; 1984 Nov; 115(5):1787-91. PubMed ID: 6208014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of inhibitors of cyclic nucleotide phosphodiesterase on actions of cholecystokinin, bombesin, and carbachol on pancreatic acini.
    Gardner JD; Sutliff VE; Walker MD; Jensen RT
    Am J Physiol; 1983 Nov; 245(5 Pt 1):G676-80. PubMed ID: 6195928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.